Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AB1 | P08238 | 8/20 | 0.48 |
| ▸ | HSP90AA1 | P07900 | 6/20 | 0.46 |
| ▸ | DHFR | P00374 | 1/20 | 0.41 |
| ▸ | NOS3 | P29474 | 2/20 | 0.40 |
| ▸ | NOS1 | P29475 | 2/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | MAOA | P21397 | 1/20 | 0.38 |
| ▸ | NOS2 | P35228 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.36 |
| ▸ | HTR2B | P41595 | 1/20 | 0.35 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18750348 | 0.90 | HSP90AB1 (0.48) | HSP90AB1HSP90AA1DHFRNOS3NOS1 | |
| SCHEMBL17349606 | 0.87 | HSP90AB1 (0.48) | HSP90AB1HSP90AA1DHFRNOS3NOS1 | |
| SCHEMBL17349615 | 0.86 | HSP90AA1 (0.47) | HSP90AB1HSP90AA1DHFRNOS3NOS1 | |
| SCHEMBL17349603 | 0.78 | HSP90AB1 (0.46) | HSP90AB1HSP90AA1DHFRCYP2C19 | |
| SCHEMBL23153299 | 0.75 | HSP90AB1 (0.44) | HSP90AB1HSP90AA1DHFRCYP2C19 | |
| SCHEMBL23153308 | 0.74 | HSP90AB1 (0.51) | HSP90AB1HSP90AA1DHFRNOS3NOS1 | |
| SCHEMBL17336023 | 0.74 | HSP90AB1 (0.50) | HSP90AB1HSP90AA1DHFRNOS3NOS1 | |
| SCHEMBL23153346 | 0.74 | HSP90AB1 (0.48) | HSP90AB1HSP90AA1NOS3NOS1CYP2C19 | |
| SCHEMBL14209035 | 0.73 | HSP90AB1 (0.49) | HSP90AB1HSP90AA1DHFRNOS3NOS1 | |
| SCHEMBL24055078 | 0.72 | HSP90AB1 (0.49) | HSP90AB1HSP90AA1DHFRNOS3NOS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210363154-A1 | PYRIMIDINE COMPOUNDS AND METHODS USING THE SAME | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. | 2021-11-25 | — | — | US | disclosed |
| US-10961254-B2 | Pyrimidine compounds and methods using the same | YUMA THERAPEUTICS, INC. (US) | 2021-03-30 | — | — | US | disclosed |
| US-10336768-B2 | Pyrimidine compounds and methods using the same | YUMA THERAPEUTICS, INC. (US) | 2019-07-02 | — | — | US | disclosed |
| US-20170107228-A1 | PYRIMIDINE COMPOUNDS AND METHODS USING THE SAME | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2017-04-20 | — | — | US | disclosed |
| WO-2015192119-A1 | PYRIMIDINE COMPOUNDS AND METHODS USING THE SAME | YUMA THERAPEUTICS, INC. (US) | 2015-12-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170107228-A1 | PYRIMIDINE COMPOUNDS AND METHODS USING THE SAME | HSP90AB2P, HSPH1, HSF1 | HSP90AB1 5/4885HSP90AA1 8/4885DHFR 80/4885 |
| US-20210363154-A1 | PYRIMIDINE COMPOUNDS AND METHODS USING THE SAME | HSP90AB2P, HSF1, HSPH1 | HSP90AB1 4/4885HSP90AA1 7/4885DHFR 135/4885 |
| US-10336768-B2 | Pyrimidine compounds and methods using the same | HSP90AB2P, HSPH1, HSF1 | HSP90AB1 5/4885HSP90AA1 8/4885DHFR 80/4885 |
| US-10961254-B2 | Pyrimidine compounds and methods using the same | HSP90AB2P, HSPH1, HSF1 | HSP90AB1 5/4885HSP90AA1 8/4885DHFR 80/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.